A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19: bamlanivimab
收藏ICPSR2023-01-01 更新2026-04-16 收录
下载链接：
https://www.openicpsr.org/openicpsr/project/194685/version/V1/view
下载链接
链接失效反馈官方服务：
资源简介：
This data comes from a randomized, international, double blind study comparing LY-CoV555 to standard of care for the primary outcome of sustained recovery during a 90-day period in hospitalized patients with COVID-19, carried out in Fall 2020. Participants were randomized 1:1 to receive either Ly-CoV555 or matching placebo. All patients received high-quality supportive care as background therapy, including the use of remdesivir. A total of 314 patients were enrolled, 163 to LY-CoV555 and 151 to placebo. The rate ratio for sustained recovery was 1.06 (95% CI, 0.77 to 1.47).
提供机构：
Department of Infectious Diseases, Rigshospitalet, Copenhagan, Denmark
创建时间：
2023-01-01
